title: N-succinyl chitosan as buccal penetration enhancer for delivery of herbal agents in treatment of oral mucositis.
abstract: Oral mucositis is one of the major side effects of cancer chemotherapy (30-76%) and radiotherapy (over 50%). Current palliative treatments of oral mucositis include specialized agents like pelifermin, platelet derived factors etc. or oral hygienic agents which suffered from various drawbacks like systemic side effect, least effect owing to fast wash out of buccal mucosa, patient unfriendly delivery systems, and mere symptomatic relief. In this research work, N-succinyl chitosan gel delivery system of microemulsified eugenol, honey and sodium hyaluronate was prepared to explore their multiple and synergistic effects on various pathological factors of oral mucositis. N-succinyl chitosan was synthesized in our laboratory and loaded with microemulsified eugenol (10% v/v), honey (10% v/v) and sodium hyaluronate (0.2% w/v) to prepare orogel with optimum pH, spreadability, mucoadhesion strength, and viscosity. In vitro eugenol release from N-succinyl chitosan gel after 8 hours in PBS (pH-6.4) was found to be 87.45±0.14%, which was better in comparison to that released from chitosan gel. Ex vivo penetration studies using rat buccal mucosal tissue also suggested better J-efflux of eugenol through N-succinyl chitosan in comparison to chitosan gel with enhancement ratio (ER) of 1.71. The antimicrobial effect of N-succinyl chitosan based orogel against S. aureus and C. albicans efficacy was found to be statistically high in comparison to chitosan based orogel as well as marketed formulation of chlorhexidine (p<0.05). The N-succinyl chitosan orogel in 5-fluoro uracil induced oral mucositis animal (Wistar rats) model showed enhanced survival ratio, weight gain and high tissue regeneration activity than chitosan gel formulation within 15 days. The formulation was successful in elevating the survival and reducing the inflammation in the oral mucosa of animals compared to disease control (p<0.05) and hence suggesting the potential of N-succinyl chitosan orogel in the treatment of oral mucositis.
authors.forename: Neha
authors.initials: N
authors.lastname: Dhawan
authors.forename: Krishan
authors.initials: K
authors.lastname: Kumar
authors.forename: A N
authors.initials: AN
authors.lastname: Kalia
authors.affiliation: Department of Pharmaceutics/ Department of Pharmacognosy, ISF College of Pharmacy, Moga- 142001 (Punjab) India. saahil70@gmail.com.
authors.forename: Saahil
authors.initials: S
authors.lastname: Arora
mesh_terms: D000818:Animals; D048271:Chitosan / Q000008:administration & dosage / Q000737:chemistry*; D016503:Drug Delivery Systems; D005054:Eugenol / Q000008:administration & dosage / Q000737:chemistry*; D005782:Gels; D006722:Honey; D006820:Hyaluronic Acid / Q000008:administration & dosage / Q000737:chemistry*; D066298:In Vitro Techniques; D009061:Mouth Mucosa / Q000378:metabolism*; D065568:Oral Mucosal Absorption; D017208:Rats, Wistar; D013280:Stomatitis / Q000188:drug therapy; D013552:Swine
chemical_list: D005782:Gels; C118639:N-succinyl-chitosan; D005054:Eugenol; D006820:Hyaluronic Acid; D048271:Chitosan